The Targeted Pulse: Adagrasib Bests Docetaxel in Pretreated KRAS G12C-NSCLC, Adding Nivolumab to Tivozanib Yields No ...
Want to test your knowledge on the latest oncology news? Check out this week’s quiz! Adagrasib (Krazati) demonstrated significantly better results than docetaxel for patients with previously treated KRAS G12C-mutated non–small cell lung cancer (NSCLC) even …